Fera Pharmaceuticals acquires portfolio of ophthalmic ointments

NEW YORK A small pharmaceutical company has acquired a portfolio of ophthalmic ointments from a generic drug maker.

Fera Pharmaceuticals announced that it had acquired all rights, title and interest to seven anti-infective ophthalmic ointments from Nycomed U.S. division Fougera that IMS Health data indicate as representing more than 80% of the ophthalmic ointment market volume.

The company said is accepting orders for one of the drugs, bacitracin, and will begin shipping it in September.